NCT07104123 Substance Use in Pregnant People - Optimizing Retention in Treatment
| NCT ID | NCT07104123 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Washington University School of Medicine |
| Condition | Substance Use Disorder (SUD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-02-02 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2026-02-02 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Substance use during pregnancy is a leading cause of maternal morbidity and mortality in the United States, with 55-80% of postpartum patients disengaging from substance use disorder (SUD) treatment within one year of delivery. Structural and social determinants of health, including housing instability, transportation barriers, and limited childcare access, further exacerbate disparities in treatment retention. This pilot study, conducted in two specialized prenatal care clinics, evaluates the feasibility and acceptability of two integrated strategies to promote sustained engagement in recovery-oriented services during the perinatal and postpartum periods. Aim 1 implements a standardized social needs screening and referral protocol to connect patients with community-based supports. Aim 2 pilots a contingency management intervention to incentivize recovery-supportive behaviors. Findings will inform the design of a larger multi-site randomized controlled trial to evaluate the impact of these interventions on treatment retention, overdose prevention, and maternal-infant health outcomes.
Eligibility Criteria
Inclusion Criteria: Confirmed viable intrauterine pregnancy at any gestational age, or within three years postpartum SUD as defined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders or clinician documentation Exclusion Criteria: Decline follow-up care at study site Require immediate hospitalization for unstable medical or psychiatric conditions making them clinically unsuitable to participate in a research study
Contact & Investigator
Jeannie C Kelly, MD, MS
PRINCIPAL INVESTIGATOR
Washington University School of Medicine
Frequently Asked Questions
Who can join the NCT07104123 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Substance Use Disorder (SUD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07104123 currently recruiting?
Yes, NCT07104123 is actively recruiting participants. Contact the research team at melissa.mills@wustl.edu for enrollment information.
Where is the NCT07104123 trial being conducted?
This trial is being conducted at Baltimore, United States, St Louis, United States.
Who is sponsoring the NCT07104123 clinical trial?
NCT07104123 is sponsored by Washington University School of Medicine. The principal investigator is Jeannie C Kelly, MD, MS at Washington University School of Medicine. The trial plans to enroll 40 participants.